April 5, 2017 / 11:23 AM / 4 months ago

BRIEF-Myriad Genetics publishes study evaluating its myPath melanoma test

1 Min Read

April 5 (Reuters) - Myriad Genetics Inc-

* Myriad Genetics -published third clinical validation study and second clinical utility study for its mypath melanoma test

* Myriad Genetics Inc says will submit reimbursement dossier to medicare and private insurers three months earlier than expected

* Myriad Genetics-3rd clinical validation study shows mypath melanoma test had overall diagnostic accuracy of 95 percent to differentiate melanoma from benign lesions Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below